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ABSTRACT 
 
 
 Obesity is the most frequent metabolic disease worldwide and the major 
risk factor for metabolic disorders such as insulin resistance and type 2 
diabetes. In response to overfeeding, excess lipids are stored in the adipocytes, 
leading to inappropriate adipose cell expansion (hypertrophic obesity), which is 
associated with local inflammation and dysregulated and insulin resistant 
adipose tissue. Hypertrophic obesity is also characterized by an inability to 
recruit and differentiate precursor cells into mature adipocytes. This is not due 
to lack of these precursor cells but instead is a consequence of an impaired 
ability to induce commitment and promote differentiation of available 
precursor cells, by inactivating inhibitory pathways, and/or activating pathways 
needed to commit and/or differentiate.  
Very recently, the zinc finger protein Zfp423 has been identified as a 
transcriptional regulator of preadipocyte determination. Zfp423 protein, indeed, 
directly binds the peroxisome proliferator-activated receptor gamma (Pparγ) 
promoter, thus promoting the gene transcription of the master regulator of 
adipocyte differentiation. Furthermore, Zfp423 protein is the point of 
convergence between the anti-adipogenic Wnt1-inducible-signaling pathway 
protein 2 (Wisp2) pathway and the pro-adipogenic bone morphogenetic protein 
4 (Bmp4) pathway. In light of this, it is now clear that alterations impacting on 
Zfp423 and Pparγ protein and/or gene expressions are at least in part 
responsible for the restricted adipogenesis observed in hypertrophic obesity.  
Increasing evidence sustains that even adipogenesis might be regulated by an 
epigenetically induced gene transcription reprogramming.  
Thus, in light of all these observations, I aimed to establish which are the 
molecular mechanisms regulating the gene expression of Zfp423 and of its 
downstream target Pparγ looking at epigenetic changes involvement.  
Experiments were performed in two cell models: 3T3-L1 and NIH-3T3 cells, 
which are committed to and uncommitted to adipocyte lineage, respectively.  
The mRNA expression of both Zfp423 and Pparγ genes are increased in 3T3-
L1 compared with NIH-3T3 cells. Furthermore, the expression differences 
among the two cellular models are not dependent on differences in the 
promoter DNA sequence of both genes, but rather to epigenetic mechanisms 
and chromatin remodeling. Indeed, performing methylation studies by bisulfite 
sequencing and nucleosomes positioning and occupancy analysis by 
micrococcal nuclease (MNase) digestion, I revealed that the DNA methylation 
status and the nucleosomes occupancy of Zfp423 and Pparγ promoter regions 
are increased in NIH-3T3 compared with 3T3-L1 cells.  
Finally, chemically-induced demethylation of the Zfp423 and Pparγ promoters 
by DNA-methyltransferase (Dnmt) inhibitor 5-Azacyditine (AZA) treatment 
promotes adipocyte terminal differentiation in the uncommitted NIH-3T3 cell 
line.  
9 
 
 
In conclusion, I demonstrated that Zfp423 and Pparγ genes, which are involved 
in adipocyte commitment and differentiation, are transcriptionally regulated by 
DNA methylation and dynamic chromatin remodeling, and that the modulation 
of the methylation status of the promoter region of these two genes is relevant 
to the regulation of adipocyte commitment and terminal differentiation in vitro.  
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1.  INTRODUCTION 
 
 
1.1 Obesity 
 
 Overweight and obesity result from a chronic imbalance between 
energy intake and energy expenditure, leading to an excessive accumulation 
of fat in adipose tissue. The current classification of overweight and obesity in 
adults is based on the body mass index (BMI). BMI, indeed, is an indirect 
measure of body fat, described as the person's weight in kilograms, divided by 
the square of height in meters (kg/m
2
) (World Health Organization 2014).  
Thus, according to World Health Organization (WHO) classification (World 
Health Organization 2014), overweight is defined as a BMI of 25 or more and 
includes pre-obesity (25-29.9) and obesity that is divided into three 
categories: Class I (30–34.9), Class II (35–39.9) and Class III (>40) (James et 
al. 2004) (Table 1). 
 
 
Classification BMI (Kg/m2 ) 
Underweight <18.5 
Normal range 18.5-24.9 
Overweight ≥25 
Pre-obese 25-29.9 
Obese I 30-34.9 
Obese II 35-39.9 
Obese III ≥40 
 
Table 1. Classification of adult underweight, overweight and obesity according to BMI. 
According to WHO, overweight is defined as a BMI equal to or more than 25 whereas obesity as 
a BMI equal to or more than 30. 
 
 
The incidence of obesity and overweight is increasing dramatically in western 
society; it was estimated that the worldwide prevalence of obesity has doubled 
between 1980 and 2014. WHO (World Health Organization 2014) estimates 
that the 38% of males and 40% of women were overweight while the 11% of 
adult males and the 15% of adult females were obese in 2014 (Figure 1).  
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Figure 1. Prevalence of obesity in adulthood. The maps indicate the adult prevalence of 
obesity respectively in males and females (World Health Organization 2014). 
 
 
Obesity is not a single disorder but a heterogeneous disease with multiple 
causes. Body weight, indeed, is regulated by a complex interaction between 
genetic, societal, environmental, and political influences (Frood et al. 2013).  
On the genetic level, many evidence has shown that predisposing genes can 
contribute significantly to the development of obesity (Silventoinen et al. 2009; 
Silventoinen et al. 2010) by interacting with environmental factors such as 
physical inactivity and unhealthy diet (Choquet and Meyre 2011).  
Twin studies suggest a heritability of fat mass of between 40% and 70% with a 
concordance rate of 0.7-0.9 between monozygotic twins compared to 0.35-0.45 
among dizygotic twins (Stunkard et al. 1986). Furthermore, it has been also 
seen that if one’s parent is obese, the own risk to develop obesity significantly 
increased compared with age and sex-matched individuals without familiarity 
of obesity, and if obesity is present during the early childhood, the individual 
chances to be obese throughout his/her own life are high compared with their 
lean counterparts.  
12 
 
 
In addition to genetics, also societal changes that modify individual behaviours, 
leading to a more sedentary life (Bauman et al. 2011), physical inactivity 
(Hansen et al. 2012), and poor dieting (Caraher et al. 2010; Perez-Escamilla et 
al. 2012), may also contribute to the increase of obesity incidence (Swinburn et 
al. 2011).  
Many evidence suggests a strong correlation between BMI and the incidence of 
several chronic diseases, such as cancer, hypertension, coronary heart disease 
(CHD), respiratory complications and diabetes mellitus (Figure 2).  
This relationship is approximately linear for a range of BMI less than 30, but 
the risk to develop the obesity-related comorbidities greatly increase for 
subjects with a BMI above 29, independently of gender (Willett et al. 1995; 
Willett et al. 1999). The development of these complications is strictly 
correlated with the increase of body fat that impairs the physiological 
functions. Indeed, an increased amount of fat results in alterations of total 
blood volume and cardiac function, whereas the distribution of fat around 
thoracic cage and abdomen impairs respiratory function by the reduction of 
respiratory compliance. Moreover, intra-abdominal visceral deposition of 
adipose tissue plays an important role in the development of hypertension, 
insulin resistance, hyperlipidemia and diabetes mellitus (Kopelman 2000). 
 
 
 
 
Figure 2. Representation of the most important comorbidities associated with obesity. 
Obesity has a multitude of adverse metabolic health consequences such as diabetes mellitus, 
hypertension, dyslipidemia, and metabolic syndrome (Kopelman 2000). 
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1.2 Diabetes 
 
 Diabetes mellitus is a group of chronic metabolic disorders 
characterized by elevated blood glucose levels (hyperglycemia) caused by 
defects in insulin secretion, insulin action or both (American Diabetes 
Association 2010).  
The vast bulk of cases of diabetes falls into two main etiopathogenetic 
categories (American Diabetes Association 2010).  
Type 1 diabetes occurs predominantly in young people and is characterized by 
an absolute deficiency of insulin, resulting from an autoimmune mediated 
destruction of β cells. Its frequency is low relative to type 2 diabetes, which 
accounts for over 90% of cases globally, and requires a daily injection of 
insulin.  
Type 2 diabetes is the most common form of diabetes mellitus and is 
characterized by increased levels of blood glucose to which individuals are 
predisposed by an interaction between genetic, social and environmental risk 
factors (Khodabandehloo et al. 2016).  
In type 2 diabetes, the hyperglycemia is initially due to a decreased insulin 
sensitivity, as a result of insulin resistance, which leads to hyperinsulinemia. 
Later on, when the pancreatic β cells are not capable of producing the amount 
of insulin needed to maintain normal glycemic status, chronic hyperglycemia 
and type 2 diabetes occur (Kahn S et al. 2006).  
Primarily strategy for type 2 diabetes treatment consists of an individualized 
approach, consisting initially of dietary control and lifestyle modifications, 
followed by oral type 2 diabetes medications and insulin therapy (American 
Diabetes Association 2015).  
The worldwide rapid increasing prevalence of type 2 diabetes is one of the 
major and serious public health burden (Tabish 2007). Type 2 diabetes reached 
an epidemic stage in line with the increasing obesity prevalence and has been 
particularly accelerated in the developing countries.  
According to the International Diabetes Federation Atlas (International 
Diabetes Federation Atlas 2013), there are 382 million people in the world 
living with diabetes, defined as a fasting plasma glucose value ≥7.0 mmol/L 
(126 mg/dl) or 2-h plasma glucose ≥11.1 mmol/l (200 mg/dl) after a load of 
glucose (World Health Organization 2006), and it is expected to afflict around 
592 million people by 2035 (International Diabetes Federation Atlas 2013) 
(Figure 3). This rise is largely driven by modifiable risk factors, such as 
physical inactivity, overweight and diet high in fat and salt (World Health 
Organization 2010).  
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Figure 3. Prevalence of diabetes in the world. The IDF Atlas (International Diabetes 
Federation Atlas 2013) figure provides a worrying indication of the future impact of diabetes on 
the global development. 
 
 
Diabetes and its complications are the major cause of morbidity and mortality 
around the world and result in higher health care costs.  
Diabetes is the well-recognised cause of premature death and disability and is 
powerfully linked with both microvascular and macrovascular complications. 
Microvascular complications affect small blood vessel and include damage to 
the nervous system (neuropathy), renal system (nephropathy) and eye 
(retinopathy) while macrovascular complications comprise coronary artery 
disease (CAD), stroke and myocardial infarction (World Health Organization 
2010). Thus, looking at the rapid growth in the number of type 2 diabetics, the 
evolution and clinical implementation of effective psychosocial interventions 
are needed (Debono and Cachia 2007). 
 
 
1.3 The relationship between obesity and type 2 diabetes  
 
 As previously mentioned, the worldwide increase in the prevalence of 
obesity largely explains the epidemic of type 2 diabetes over the past twenty 
years (Eckel et al. 2011). According to Ford and colleagues (Ford et al. 1997), 
the risk to develop diabetes increases between 4.5 and 9% for every kilogram 
of weight increase.  
In 1995, the worldwide obese population was calculated to be around 200 
million, while the subjects considered obese, in 2014, are 600 million. 
15 
 
 
Strikingly similar trends have been observed in type 2 diabetes statistics, and 
future predictions are alarming (King et al. 1998).  
For this reason, Sims and colleagues (Sims et al. 1973), coined the term 
‘diabesity’ to explain the close relationship existing between these two 
diseases. Obesity and type 2 diabetes often occur together and the risk to 
develop type 2 diabetes for a BMI over 35, compared to a BMI less than 23, 
increases by 50-80 fold (Figure 4) (Chan et al. 1994). 
 
 
 
 
Figure 4. BMI and type 2 diabetes risk. The relationship between BMI and risk to develop 
type 2 diabetes, derived from data extracted from Chang and colleagues (Chan et al. 1994). 
 
 
Therefore, excess weight is the primary risk factor for type 2 diabetes. 
Nevertheless, obesity is not a homogeneous condition. Indeed, approximately 
10-30% of obese individuals do not show the associated metabolic 
complications and, for this reason, are defined as metabolically healthy 
individuals (Kloting et al. 2010). Nevertheless, a similar number of non-obese 
individuals show a dysmetabolic state and reduced insulin sensitivity (Scott et 
al. 2014). Thus, BMI per se is not a sufficiently sensitive marker of individual 
risk for obesity-related metabolic complications.  
Conversely, increasing evidence suggests that adipose tissue distribution might 
be a more relevant marker for obesity-related metabolic complications. Indeed, 
abdominal distribution markedly increases both cardiovascular and diabetes 
risk (Fox et al. 2009; Despres and Lemieux 2006).  
This finding has raised much interest in the possible role of regional 
differences in adipose tissue metabolism and, in particular, in the role of intra-
abdominal and visceral fat in metabolic complications (Després and Lemieux 
2006; Neeland et al. 2012).  
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1.4 Adipose tissue 
  
 Adipose tissue is a complex organ with heavy effects on physiology and 
pathophysiology. For many years, adipose tissue has been ignored because was 
considered just as a form of connective tissue, containing lipid droplets but 
without any link with the metabolism of the organisms (Rosen and Spiegelman 
2014; Rosen and Spiegelman 2006). Nevertheless, this notion gradually began 
to shift with the realization that adipose tissue takes on a critical role in energy 
homeostasis and in the regulation of metabolic functions.  
Adipose tissue is indeed a metabolically active tissue, consisting of lipid-filled 
cells, called adipocytes, that make up the 90% of the tissue volume (Lee et al. 
2010). In addition, to mature adipocytes, fat tissue contains several 
metabolically active and inflammatory cells, including stromal vascular cells 
such as fibroblasts, leukocytes, macrophages, pericytes, endothelial cells, and 
preadipocytes, which take on a significant part in the integrity of tissue (Katz 
2002).  
The mammalian adipose tissue is divided into two functionally distinct forms 
of fat: white and brown. White adipose tissue is the primary site of energy 
storage (Ronti et al. 2006; Rosen and Spiegelman 2006) but can act also as a 
thermal insulator and protect other organs from mechanical damage (Trayhurn 
2007). Brown adipose tissue, on the other hand, is highly specialized in the 
dissipation of stored chemical energy by the generation of heat by the actions 
of mitochondrial uncoupling protein-1 (UCP-1), a brown adipose tissue-
specific protein located within the mitochondria (Rosen and Spiegelman 2014; 
Rosen and Spiegelman 2006). Nevertheless, the concept of two different forms 
of adipose tissue has been altered after the recognition that brown fat cells 
might be interspersed in the white adipose tissue to form “beige cells” 
(Boström et al. 2012). A recent study has shown that the fully stimulated 
brown and beige adipocytes contain comparable amounts of UCP-1, suggesting 
that they have a similar thermogenic capacity (Wu et al. 2012).  
 
 
1.4.1 White adipose tissue as link between obesity and type 2 diabetes  
 
As above mentioned, the main functions of white adipose tissue are: i) 
to store calories in the form of lipid droplets after food intake; ii) to release fat 
during the fasting state; iii) to cushion the body parts and to protect delicate 
organs from mechanical stress.  
Furthermore, white adipose tissue plays a critical role in the energy balance 
and nutritional homeostasis (Rosen and Spiegelman 2014).  
In humans, white adipose tissue constitutes the largest endocrine organ and is 
certainly so in overweight and obese individuals. Therefore, even minor 
metabolic changes in such a large secretory organ can impact on the whole-
body metabolism (Trayhurn 2007).  
17 
 
 
White adipocytes in addition to store fatty acids, produce and release also a 
wide range of lipid, hormones and cytokines (adipokines) such as leptin, 
interleukin 6, adiponectin, monocyte chemoattractant protein 1 and tumour 
necrosis factor alpha, that are required for many biological functions as glucose 
and lipid metabolism, insulin sensitivity, inflammation, coagulation, blood 
pressure and feeding behaviour (Van Gaal et al. 2006; Müller et al. 2012; 
Wildman et al.  2008; Klein et al. 2004) (Figure 5).  
 
 
 
 
Figure 5. Adipose Tissue as an endocrine organ. Adipose tissue is an endocrine organ that 
secretes various hormones and adipokines involved in the many physiological and metabolic 
processes (Trayhurn 2013). 
 
 
The white adipose organ includes multiple discrete locations (Lee et al. 2014; 
Shen et al. 2003). The most common classification distinguishes between 
subcutaneous and visceral fat (Figure 6) that are characterized by functional 
differences. Subcutaneous adipose tissues store more than 80% of total body 
fat in the body and is located beneath the skin; while visceral fat is around 
internal organs and comprises less that 10% of the total fat mass.  
Being involved with its expansion in the development of obesity, white adipose 
tissue is now seen as the epicenter of the disorder and its associated 
comorbidities (Greenberg and Obin 2006).  
Many studies have, indeed, shown that total adiposity is strongly associated 
with metabolism and cardiovascular risk. More, it has been also determined 
that the various fat depots contribute differently to this risk (Hassan et al. 
2012). Indeed, the accumulation of visceral fat seems to correlate with an 
increased prevalence of insulin resistance, metabolic syndrome, and 
cardiovascular complications (Lemieux et al. 1996) whereas the fat 
accumulation in the peripheral subcutaneous adipose tissue does not seem to be 
associated with many of these obesity-related comorbidities (Porter et al. 
2009).  
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A key role in the regional variation in fat tissue function is also played both by 
regional differences in preadipocytes characteristics (replication, 
differentiation, subtype abundance, susceptibility to apoptosis or senescence 
and gene expression) and by some aspects of adipocyte behavior (adipokine 
secretion, rates of lipolysis and triglyceride synthesis) (Tchkonia et al. 2010; 
Tchkonia et al. 2013).  
 
 
Figure 6. Representation of the anatomical localization of the main abdominal adipose 
tissue depots. There are two major types of fatty tissue in the body: visceral and subcutaneous 
adipose tissue (Lee et al. 2014; Shen et al. 2003). 
 
 
 
1.4.2 White adipose tissue remodeling in obesity   
 
White adipose tissue is characterized by an incredible ability to change 
its dimension (Rosen and MacDougald 2006; Rosen and Spiegelman 2014; 
Rosen and Spiegelman 2006), in response to nutrient excess or insufficiency 
(Martinez-Santibañez and Nien-Kai Lumeng 2014); this is essential for the 
maintenance of whole-body energy homeostasis.  
White adipose tissue expansion is primarily achieved i) by increasing the size 
of individual adipocytes (hypertrophy), or ii) by recruiting new adipocytes 
from the resident pool of progenitors (hyperplasia) (Rosen and Spiegelman 
2014).  
In response to overfeeding, adipose depots expand first by hypertrophy, until a 
critical threshold    0.7-0.8 µg/cell) is reached (Krotkiewski et al. 1983).  
As shown by several studies, the balance between these two mechanisms 
depends on the location of the fat pad. However, in humans, the mechanisms of 
adipose tissue expansion during obesity are not fully delineated yet.  
Anyway, many evidence suggests that overfeeding for several months induces 
an increase in cell size (Salans et al. 1971). A late version of this study 
suggests that acute excess of calories induces hypertrophy in the upper body 
subcutaneous fat and hyperplasia in the fat depots located below the waist 
(Tchoukalova et al. 2010). 
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 More recently, Spalding and colleagues (Spalding et al. 2008), shown that 
“new adipocytes are generated constantly to replace lost adipocytes” and 
estimated that the half-life of the average adipocyte is in the order of 8.3 years 
(Sun et al. 2011). Moreover, it has been demonstrated that the number of 
adipocytes becomes already fixed in childhood and early adulthood (Sun et al. 
2011; Spalding et al. 2008) and that significant weight loss is associated only 
with reduction of adipocyte volume and not of their number.  
The last suggests that hypertrophy of adipocytes is the most significant 
mechanism by which white adipose tissue mainly undergoes alterations during 
adulthood (Spalding et al. 2008; Sun et al. 2011).  
Nevertheless, as stated previously, the mechanisms by which adipose tissue 
expands in humans in obesity are not fully defined, and the patterns of fat 
deposition and expansion vary between people. This variance in adipose tissue 
distribution appears to determine the differences found in metabolic disease 
risk seen among individuals with a similar level of adiposity.  
Many evidence suggests that in obese individuals, the metabolic dysfunction is 
related to large adipocytes, and is associated with the impaired ability to 
develop new cells (Hammarstedt et al. 2012; Isakson et al. 2009). 
On the contrary, others indicate that an overabundance of small adipocytes is 
associated with a more unhealthy metabolic phenotype (McLaughlin et al. 
2010; McLaughlin et al. 2007). In both instances, the final result is the same.  
Indeed, the ability of the white adipose tissue to act as an efficient storage 
depot is impaired, inducing other peripheral tissues to compensate by 
accumulating inappropriately lipids.  
Thus, the impairment in the ability of white adipose tissue to generate new 
cells through differentiation of preadipocytes is associated with the 
development of insulin resistance and diabetes mellitus (Karastergiou and 
Mohamed-Ali 2010) and the enlargement of adipocytes (hypertrophy) is 
correlated with death of adipocytes by necrosis, leading to local inflammation 
and recruitment of monocytes as a response (Strissel et al. 2007; Cinti et al. 
2005).   
 
 
1.4.2.1 Hypertrophic obesity: restricted adipogenesis and inflammatory 
 response 
  
As above mentioned, white adipocyte hypertrophy is characterized by 
the presence of large, lipid-laden adipocytes and may result from an 
intrinsically reduced capacity of de novo adipogenesis (Klöting and Blüher 
2014).  
In addition to the last observations, Smith and colleagues, analysing 
adipogenesis in stromal vascular cells from human abdominal subcutaneous 
depots (Gustafson and Smith 2012), have found poor differentiation in 
individuals with large subcutaneous adipose cells (hypertrophic obesity), 
whereas small adipose cells were associated with good adipogenesis, 
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suggesting thus a causal relationship between restricted adipogenesis and 
adipose cell volume (Figure 7).  
Furthermore, these differences were not due to lack of precursor cells in 
hypertrophic obesity, but rather to the inappropriate signaling of pathways 
which promotes precursor cell differentiation and/or which enhances inhibitory 
signals promoting dedifferentiation (Talchai et al. 2012). 
Unlike to hyperplastic obesity, many human studies have demonstrated that 
adipocyte hypertrophy is negatively correlated with the impairment of glucose 
and lipid metabolism and with the loss of insulin sensitivity, independently by 
the grade of obesity measured as BMI (Smith and Hammarstedt 2010; Blüher 
2013; Klöting and Blüher 2014) and, plays a key function as an independent 
predictor of future type 2 diabetes onset (Lönn et al. 2010).  
 
 
 
 
Figure 7. The distinction of human preadipocytes from the abdominal subcutaneous 
adipose tissue is concerned to the adipose cell size of the donors. Purified stromal 
vascular cells were differentiated for 21 days in vitro and then stained with Oil Red O to show 
the lipid droplets (top).The negative correlation between the amount of lipids accumulated 
during differentiation and the adipose cell size of the donors is shown (bottom) (Gustafson and 
Smith 2012). 
 
 
Bluher and colleagues (Klöting and Blüher 2014), have furthermore 
demonstrated that adipocyte volume is associated not only with significantly 
impaired whole-body insulin sensitivity but also with increased circulating 
factors of inflammation, oxidative stress and an increased number of 
macrophage infiltration within adipose tissue (Klöting and Blüher 2014; Blüher 
2013). Altogether these alterations cause local chronic low-grade inflammation 
(Sell et al. 2012; Bastard et al. 2006; Weisberg et al. 2003) (Figure 8).  
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The response of adipocytes, macrophages and other adipose tissue cells to 
these stress stimuli contributes to the deterioration of cellular functions and to 
the metabolic comorbidities associated with obesity (Rudich et al. 2007; 
Bashan et al. 2007). E.g., intracellular kinases involved in the transmission of 
the stress response, such as p38 and Jun N-terminal kinase, are upregulated and 
activated in adipose tissue of individuals with adipocyte hypertrophy (Bashan 
et al. 2007). Furthermore, a recent study suggests that in addition to adipocytes 
also macrophages in adipose tissue are exposed to the stress and may mediate 
the link between adipose tissue stress-response and the risk of obesity-induced 
metabolic diseases and inflammation. In addition, macrophages may report to 
other organs the stress and inflammatory status of the adipose tissue, leading to 
secondary organ failure. 
In conclusion, hypertrophic obesity may start a sequence of pathogenic event 
that contributes to adipose tissue dysfunction and may subsequently have 
negative effects on other tissues (Blüher 2013). 
 
 
 
 
Figure 8. Adipose tissue expansion. Healthy and unhealthy adipose tissue expansion during 
weight gain. (A) Healthy adipose tissue expansion comprises of an enlargement of adipose 
tissue through effective recruitment of adipogenic precursor cells to the adipogenic program. (B) 
In contrast, pathological adipose tissue expansion consists of an expansion of existing 
adipocytes, limited angiogenesis, and resulting hypoxia. Ultimately, the expansion of the 
adipose tissue leads to the recruitment of macrophages through various signals synthesized by 
adipocytes. These macrophages are found mainly around apoptotic adipocytes and M1-stage 
macrophages prevail, leading to an inflammatory phenotype that is powerfully linked with 
systemic insulin resistance (Sun et al. 2011). 
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1.4.2.2 Hypertrophic obesity: adipose tissue expandability and ectopic fat 
 accumulation  
  
 Adipose tissue expandability in response to positive energy balance has 
been considered an adaptive process. However, recent evidence suggests that 
adipose tissue expandability may play an important role in the development of 
the obesity-associated comorbidities (Slawik and Vidal-Puig 2006).  
In particular, the subcutaneous adipose tissue has a higher capacity to expand 
its capillary network compared with visceral adipose tissue, but with the gain 
of fat mass (hypertrophy) this capacity decreases and, as a consequence, fat is 
stored in other metabolically more harmful ectopic lipid depots, such as intra-
abdominal and visceral sites, liver, myocardium, and skeletal muscles 
(Gealekman et al. 2011; Van Harmelen et al. 2004; Bouloumie et al. 2002; 
Rupnick et al. 2002).  
Many evidence suggests that both the restricted adipogenesis that the impaired 
tissue vascularization capacity play a critical role in the reduction of 
subcutaneous adipose tissue expandability and are responsible for the 
development of metabolic disorders (Gealekman et al. 2011; Van Harmelen et 
al. 2004); furthermore decrease in tissue expandability in humans positively 
correlates with whole body insulin resistance (Gealekman et al. 2011). 
The inability of subcutaneous adipose tissue to expand proportionally to caloric 
excess represents an important junction in the development of adipose tissue 
dysfunction and ectopic fat accumulation (Blüher 2013; Van Harmelen et al. 
2004; Bouloumie et al. 2002; Rupnick et al. 2002), defined as the accumulation 
of excess energy as fat in locations not classically associated with adipose 
tissue storage (Britton et al. 2011; Gustafson et al. 2007). 
 Ectopic fat depots can induce both systemic (as visceral adipose tissue and 
intrahepatic fat) that local effects (as pericardial, myocardial and perivascular 
fat) (Figure 9). Nevertheless, the mechanisms underlying the connection 
between obesity, body fat distribution, and metabolic derangements remain still 
incompletely understood (Cornier at al. 2011).  
 
 
 
Figure 9. Classification of ectopic fat. Ectopic fat depots in non-adipose tissues, promotes 
systemic and local effects, including dysfunction, insulin resistance, and inflammation in the 
liver, muscular tissue, pancreas and visceral fat (Britton et al. 2011). 
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As stated previously, lipids can accumulate abnormally in hepatocytes, leading 
to an abnormal fat accumulation in the liver that is well known as a 
nonalcoholic fatty liver disease (NAFLD).  
NAFLD is characterized by various hepatic abnormalities that ranging from 
hepatic steatosis to non-alcoholic steatohepatitis (NASH). Furthermore, the 
resulting accumulation of fat in hepatocytes can lead to hepatic insulin 
resistance, impairment in the insulin-mediated suppression of hepatic glucose 
production and hence fasting hyperglycemia (Lee et al. 2014). In addition, fatty 
acids impair the ability of hepatocytes to degrade insulin, leading to 
hyperinsulinemia, and provide substrates for triglyceride synthesis, 
contributing to hyperlipidemia by elevated hepatic very low-density lipoprotein 
(VLDL)-triglyceride secretion combined with elevated high-density lipoprotein 
(HDL)-cholesterol clearance (Choi and Ginsberg 2011).  
On the other hand, ectopic fat accumulation surrounding the heart and blood 
vessels is assumed to have mostly local effects.  
the epicardial adipose tissue under normal conditions is thought to serve a 
number of physiologic functions, including acting as an energy source to the 
myocardium by releasing fatty acids (Gustafson 2010; Gustafson et al. 2007; 
Talman et al. 2014).  
Moreover, epicardial fat may directly affect the coronary arteries and 
myocardium through paracrine actions of locally secreted adipokines and other 
bioactive molecules (Ricote et al. 1998; Tannock et al. 2004), which promote 
macrophage infiltration into adipose tissue, and locally reduce insulin-induced 
vasodilatation, leading to vasoconstriction (Chen et al. 2001).  
These alterations might have long-term effects on cardiovascular function and 
morphology and might be responsible for cardiovascular disorders (Ricote et 
al. 1998). 
 
 
1.5 Adipocyte differentiation: pro- and anti-adipogenic pathways 
  
The generation of adipocytes from precursor stem cells takes a complex 
and temporally regulated program of gene expression that is termed 
adipogenesis (Rosen and MacDougald 2006; Rosen and Spiegelman 2014; 
Rosen and Spiegelman 2006). At the cellular level, adipogenesis is divided into 
two phases: determination and terminal differentiation. 
During determination, precursor cells became committed to adipocyte lineage 
and are identified as preadipocytes.  
These cells cannot be distinguished morphologically from their precursors, but 
lost the potential to differentiate into other cell types In the second phase, 
known as terminal differentiation, preadipocyte acquires the machinery 
required for transport and synthesis of lipids, for responsiveness to insulin and 
for the secretion of adipocyte-specific proteins (Rosen and MacDougald 2006; 
Rosen and Spiegelman 2014).  
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The molecular regulation of terminal differentiation is more extensively 
characterized than the commitment, which has not been entirely understood yet 
(Rosen and Spiegelman 2014). 
Several transcription factors, such as Pparγ and CCAAT/enhancer binding 
protein alpha (C/EBPα) (Wu et al. 1999) have been identified to be a regulator 
of adipocyte differentiation by activating adipocyte-specific genes (Niemelä et 
al. 2008) (Figure 10).  
In details, Pparγ is a member of the nuclear receptor superfamily that plays an 
important role in the control of gene expression linked to a variety of 
physiological processes. Its most notable function is to regulate development of 
adipose tissue, which involves coordinating expression of many hundreds of 
genes responsible for the establishment of the mature adipocyte phenotype 
(Tontonoz et al. 1994; Evans et al. 2004; Farmer 2005).  
In addition to Pparγ, Zfp423 was recently identified as a transcriptional 
regulator of preadipocyte commitment (Gupta et al. 2010; Cawthorn et al. 
2012). Indeed, work from the Spiegelman lab showed that the Zfp423 
transcription factor is enriched in adipogenic fibroblast cell lines, relative to 
non-adipogenic cells. Although Zfp423 is not upregulated during adipogenesis, 
ectopic expression of Zfp423 in non-adipogenic cells is sufficient to activate 
Pparγ expression and markedly increases the adipogenic potential of these cells 
(Gupta et al. 2010). Conversely, reduction of Zfp423 expression in 3T3-L1 
preadipocytes or mouse embryonic fibroblasts blunts preadipocyte Pparγ 
expression and diminishes the ability of these cells to differentiate.  
 
 
 
Figure 10. Adipocyte differentiation and gene expression. The major identified events of 
preadipocyte differentiation are presented chronologically. Areas labeled with gene names 
represent periods of gene expression in the differentiation program. The discrete levels of 
differentiation (very early, early, intermediate and late) are likewise offered. LPL, lipoprotein 
lipase; MIX, methyl isobutyl xanthine; DEX, dexamethasone (Ntambi and Young-Cheul 2000). 
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In addition to the previously mentioned proteins, other signaling pathways are 
involved in the regulation of commitment and adipogenesis such as the 
canonical WNT signaling pathway (Isakson et al. 2009; Logan and Nusse 
2004).  
WNT family members are secreted glycoproteins that regulate adult tissue 
homeostasis and remodeling by autocrine and paracrine mechanisms (Logan 
and Nusse 2004; Taipale and Beachy 2001), and exert their effects by signaling 
through multiple so-called ‘canonical’ and ‘non-canonical’ pathways.  
Various reports have implicated WNT signaling molecules in the regulation of 
mesenchymal stem cell proliferation, cell fate determination and preadipocyte 
differentiation as well (Christodoulides et al. 2009) (Figure 11).  
Specifically, the canonical WNT pathway activation in 3T3-L1 preadipocytes 
through the overexpression of WNT1 inhibits adipogenesis (Ross et al. 2000). 
Furthermore, other studies have demonstrated that the WNT signaling 
represses adipogenesis also by blocking the induction of Pparγ and C/EBPα 
(Christodoulides et al. 2009).  
 
 
 
 
Figure 11. The canonical WNT signaling cascade converges on the transcriptional regulator ß-
catenin (Logan and Nusse 2004). In the absence of WNT signals, cytoplasmic ß-catenin is 
degraded by the action of the axin and adenomatous polyposis coli (APC) complex, which 
facilitates its phosphorylation by casein kinase I (CK1) and glycogen synthase kinase 3-beta 
(GSK3-ß), resulting in ß-catenin ubiquitination and proteasomal degradation (He et al. 2004). 
On the contrary, when a WNT ligand binds to the frizzled (FZ) receptors and the low-density-
lipoprotein-receptor-related Protein-5 or -6 (LRP5/6) co-receptors, the ß-catenin degradation is 
inhibited and ß-catenin translocates to the nucleus, where forming complexes with the lymphoid 
enhancer binding factor/T cell specific transcription factor (LEF/TCF) family, activates WNT 
target gene expression. 
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WNT signaling pathway thus plays a critical role in maintaining precursor cells 
uncommitted and undifferentiated (Isakson et al. 2009; Clevers and Nusse 
2012) and its termination is a prerequisite to allowing induction of adipogenic 
differentiation. However, WNT inhibition is necessary, but not sufﬁcient to 
induce commitment of the mesenchymal stem cells and of other adipogenic 
precursor cells. Indeed, additional signals are needed to be turned on or to be 
repressed in order to start the differentiation process.  
E.g., the Bone Morphogenetic Proteins have been shown to play an important 
role in the induction of both white adipogenesis (Bmp2 and 4) and brown 
adipogenesis (Bmp7) (Bowers et al. 2006; Gustafson and Smith 2012; Tseng et 
al. 2008).  
In particular, it has been recently demonstrated that Bmp4, which is a member 
of the transforming growth factor beta superfamily, induces the commitment 
and the subsequent adipogenesis of human subcutaneous adipose precursor 
cells (Gustafson and Smith 2012).  
Interestingly, the pro-adipogenic effect of Bmp4 was likewise seen in adipose 
precursor cells from people with hypertrophic obesity supporting the idea that 
mesenchymal stem cells and other early precursor cells are present in the white 
adipose tissue and may be recruited following appropriate pro-adipogenic 
signals. In addition to the previously described findings, Smith and colleagues 
(Hammarstedt et al. 2013; Gustafson et al. 2013) have identified the Wisp2 
protein as a novel adipokine involved in the crosstalk between WNT and Bmp4 
signaling.  
Their ﬁndings have indeed shown that Wisp22 protein, which is highly 
expressed in early adipogenic precursor cells, and, in particular, results to be 
upregulated in the subcutaneous adipose tissue of individuals with hypertrophic 
obesity, is able to inhibit adipogenesis by exerting a direct extracellular 
inhibitory signal on Pparγ activation and adipose cell differentiation as well as 
by preventing the effect of Bmp4 to induce precursor cell commitment.  
Inside cells, the cytosolic Wisp2 protein forms a complex with the 
transcriptional regulator of preadipocyte determination Zfp423, preventing thus 
the Bmp4-induced Zfp423 translocation into the nucleus and the Zfp423-
mediated regulation of Pparγ gene expression (Hammarstedt et al. 2013; 
Gustafson et al. 2013) (Figure 12). 
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Figure 12. Regulation of precursor cell commitment by Bmp4 and subsequent 
differentiation of the preadipocytes. Precursor cells are kept undifferentiated by WNT 
activation and the intracellular and secreted mediator Wisp2. Wisp2 preventing Pparγ activation 
by binding ZNF423/Zfp423 in the cytosol. Bmp4 induces Smad1/5/8 phosphorylation, which 
interacts with the Smad binding sites in ZNF423/Zfp423, dissociates the complex, allowing 
ZNF423/Zfp423 to enter in the nucleus and initiate Pparγ activation. This allows the cellular 
commitment, but overall differentiation is also regulated by extracellular Wnt/Wisp2, which 
prevents Pparγ activation through still unclear mechanisms (Hammarsted et al. 2013). 
 
 
1.6 Epigenetics and adipogenesis   
 As previously mentioned, obesity is a multifactorial disease and is 
caused by the combined action of genetic and environmental factors.  
The presence of a hereditary component in obesity is fully supported by twin-
based studies. The hereditability of BMI in twins indeed ranges from 40 to 
70% (Stunkard et al. 1986). With regard to the genetic component, several 
obesity forms are recognized. Monogenic obesity is determined by mutations 
in the genes for leptin, proopiomelanocortin, or melanocortin receptors 3 or 4 
(Shapira et al. 2005). However, despite the strong familial clustering of obesity 
and the identification of several common variants, genome-wide association 
studies provide the limited capacity to predict risk genes for obesity.  
Thus, the complexity of obesity cannot be entirely accounted by genetic 
causes. The observed familial clustering of obesity may thus be attributable to 
a significant epigenetic component.  
With the term epigenetics are defined all the heritable and reversible changes in 
gene activity and expression that occur without alteration in DNA sequence 
(Herrera et al. 2011; Choi et al. 2013). Nowadays, epigenetics is recognized as 
a more than the plausible link between environment (wrong feeding behavior, 
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physical inactivity, smoking, etc.) and alterations in gene expression that might 
lead to disease phenotypes (El-Osta et al. 2008; Jirtle and Skinner 2007).  
Thus, environmental exposures to nutritional, chemical and physical factors 
have the potential to alter gene expression and to modify adult disease 
susceptibility (obesity and type 2 diabetes) in various ways through changes in 
the epigenome (Jirtle and Skinner 2007), and the implications of different 
epigenetic processes in obesity onset are now being extensively investigated 
(Martínez et al. 2014).  
Epigenetic alterations are often tissue specific and include DNA methylation 
and histone modifications which mediate several biological processes such as 
imprinting (Herrera et al. 2011). For instance, gestational metabolic 
programming by environmental cues is an important determinant of obesity 
predisposition.  
Alterations in the DNA methylation pattern in intrauterine life are indeed 
capable of changing gene expression of several genes, and of contributing to 
the risk to develop obesity by increasing adipose tissue growth and expansion.  
Even adipogenesis might be regulated by an epigenetically induced gene 
transcription reprogramming. E.g., Fujiki and colleagues (Fujiki et al. 2009), 
have demonstrated that the promoter of the Pparγ2 gene is hypermethylated in 
3T3-L1 preadipocytes, but, following the induction of differentiation, it 
undergoes demethylation and the Pparγ2 mRNA expression increases as 
demethylation proceeds (Fujiki et al. 2009).  
In addition, others have also shown that the promoter regions of late 
adipogenic genes, such as the insulin-responsive Glut4 and leptin are 
demethylated during adipogenesis as well, and that this event is paralleled by a 
correspondent increased expression of these genes in mature adipocytes 
(Pinnick and Karpe 2011). Furthermore, Martinez and colleagues have recently 
provided high-resolution views of chromatin remodeling during cell 
differentiation and have allowed the designation of thousands of putative 
preadipocyte- and adipocyte-specific, cis-regulatory elements based on 
dynamic chromatin signatures (Martinez et al. 2014).  
Therefore, based on the last examples there are at least two ways by which 
epigenetic modifications may influence the adipogenic programs.  
The first one is by increasing or decreasing the levels of primary transcription 
factors, such as Pparγ, through the direct epigenetic regulation of their 
promoters. The second one is, instead, by assembling either activator or 
repressor multiprotein complexes to master transcription factor promoter 
regions. These proteins are localized downstream the promoter regions 
possessing specific recognition sequences, and often they operate including or 
excluding epigenetic modifying enzymes. 
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2. AIM OF THE STUDY 
 
 
 Hypertrophic obesity is typically associated with the development of 
insulin resistance and type 2 diabetes. It is due to the inability to recruit and 
differentiate available precursor cells in the subcutaneous adipose tissue, 
through the inactivation of canonical WNT signaling pathway, allowing Bmp4 
to initiate their commitment (Hammarstedt et al. 2013; Gustafson et al. 2013). 
Emerging evidence suggests that the zinc-finger protein Zfp423 (a key 
mediator of Bmp4 pathway) controls preadipocyte determination directly 
regulating Pparγ gene expression (Gupta et al. 2010). 
The elucidation of the molecular mechanisms regulating the expression of 
Zfp423 and its downstream target Pparγ would be useful to understand the 
causes of the restricted adipogenesis observed in hypertrophic obesity.  
Genetic studies performed so far have not identified genetic variants of Zfp423 
and Pparγ genes associating with hypertrophic obesity.  
Furthermore, the complexity of obesity cannot be entirely accounted for 
genetic changes and the obesity-related comorbidities may be attributable to a 
significant epigenetic component.  
For this reason, this work aims at investigating the contribution of epigenetic 
mechanisms to the transcriptional regulation of Zfp423 and Pparγ genes.  
Understanding of the molecular mechanisms regulating Zfp423 and Pparγ 
expression will help the identification of novel strategies aimed at preventing 
and treating the restricted adipogenesis typical of hypertrophic obesity.  
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3. MATERIALS AND METHODS 
 
 
3.1 Materials 
 
 Media, sera, and antibiotics were purchased from Invitrogen (Paisley, 
UK). Rosiglitazone was purchased from Alexis (Milan, Italy). AZA, 3-
isobutyl-1-methylxanthine and dexamethasone were from Sigma-Aldrich (St 
Louis, Missouri, USA). Insulin, TRIzol, and SuperScript III were from 
Invitrogen (Carlsbad, California, USA). pCpGfree-Lucia was from InvivoGen 
(St Diego, California, USA). SYBR Green Supermix was from Bio-Rad 
(Hercules, California, USA). EZ DNA Methylation Kit was from Zymo 
Research (Orange, California, USA). Micrococcal Nuclease, Dam
-
/Dcm
- 
E.coli 
cells, HpyCH4IV enzyme and M.SssI, HhaI and HpaII methylases were 
purchased from New England Biolabs (Ipswich, Madison, USA). DNA 
Purification Kit and pGEM-T EASY Vector were from Promega (Madison, 
Wisconsin, USA). The QIAquick PCR Purification kit was from QIAGEN 
(Hilden, Germany). Big Dye Terminator v3.1 Cycle Sequencing Kit was from 
Applied Biosystems (Foster City, California, USA). PCR clean-up and gel 
extraction were from Macherey-Nagel (Neumann Neander, Duren, Germany). 
 
 
3.2 Cell culture, treatment and adipocyte differentiation  
 
 3T3-L1 and NIH-3T3 mouse embryonic fibroblasts were obtained from 
the American Type Culture Collection (Manassas, Virginia, USA). They were 
cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) 
supplemented with 10% calf serum (CS), penicillin (200 IU/ml) and 
streptomycin (100 g/ml). Cells were maintained at 37° in a humidified CO2 
incubator.  
For adipocyte differentiation assays, cells were grown to confluence in medium 
containing 10% CS. Two days after confluence, cells (day 0) were cultured in 
DMEM supplemented with a differentiation cocktail containing 5 g/ml 
insulin, 0.5 mmol/l 3-isobutyl-1-methylxanthine (IBMX), 1 mol/l 
dexamethasone (DEX), 1 μM rosiglitazone and 10% fetal bovine serum (FBS), 
for 2 days. Forty-eight hours after induction, cells were maintained in DMEM 
containing insulin  5 μg/ml) and 10% FBS until they were ready for collection.  
The NIH-3T3 cells were cultured in the presence or absence AZA (5 μM) for 
6h before the administration of differentiation cocktail.  
Lipid accumulation of mature adipocytes was determined by Oil red O 
staining, as described by Isakson and colleagues (Isakson et al. 2009) and, 
quantified as an index of differentiation.  
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The cells were fixed in 4% formaldehyde and incubated for 20 min at room 
temperature. The formaldehyde was removed by washing the samples for 5 
min in PBS.  
Then, the cells were incubated for 60 min at RT in Oil Red O staining solution. 
Images were taken using an Olympus microscope system (Olympus, Center 
Valley, Pennsylvania, USA). For quantification, absorbance was measured at 
510 nm using a spectrophotometer (Beckman, California, USA), after the 
addition of isopropanol and the incubation at room temperature for 10 minutes. 
 
 
3.3 Rna isolation and real time RT-PCR  
 
 Total RNA was isolated by the TRIzol reagent, according to the 
manufacturer’s protocol. Upon adding chloroform, the RNA remains in the 
aqueous phase, while proteins and high molecular weight DNA enter the 
organic phase and the interphase, respectively.  
Total RNA is recovered by isopropanol  precipitation. Reverse transcription of 
1 µg of total RNA was performed using SuperScript III following the 
manufacturer’s instructions. The cDNA obtained were used as a template for  
quantitative real time RT-PCR, performed in triplicate by using iQ SYBR 
Green Supermix on iCycler real time detection system (Bio-Rad). Relative 
quantification of gene expression was calculated by the ΔΔ-Ct method. Each Ct 
value was first normalized to the respective Cyclophilin Ct value of a sample to 
account for variability in the concentration of RNA and in the conversion 
efficiency of the reverse transcription reaction. The primers used are listed in 
the table below (Table 2).  
 
C/EBPα Forward 5’-GGCTCGCCATGCCGGGAGAA-3’ 
Reverse 5’-CCGGGTCGATGTAGGCGCTG -3’ 
Pparγ2 Forward 5'-CAGTGGAGACCGCCCAGGCT- 3' 
Reverse 5'-TGGAGCAGGGGGTGAAGGCT- 3' 
Fabp4/Ap2 Forward 5'-TCTCACCTGGAAGACAGCTCC- 3' 
Reverse 5'-GCTGATGATCATGTTGGGCTTGG- 3' 
Glut4 Forward 5′-CAGAAGGTGATTGAACAGAG-3′ 
Reverse 5′-AATGATGCCAATGAGAAA-3 
AdipoQ Forward 5'-GTGACGACACCAAAAGGGCTC -3' 
Reverse 5' -TCCAACCTGCACAAGTTCCC- 3' 
Cyclophilin Forward 5'-GCAGACAAAGTTCCAAAGACAG- 3' 
Reverse 5'-CACCCTGGCACATGAATCC- 3' 
 
Table 2. Primer sequences used in quantitative real time RT-PCR analysis. 
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3.4 MNase protection assay 
 
 Chromatin was analysed by an MNase that is an endo-exonuclease with 
the ability to induce double strand breaks in the linker region between 
individual nucleosomes, leading to the characteristic nucleosomal ladder. 
Because of this property, MNase can be used to determine the approximate 
positions of nucleosomes in a region of DNA, if the nucleosomes are 
consistently positioned (Richard-Foy and Hager 1987).  
For each experiment, NIH-3T3 and 3T3-L1 cells were fixed for 10 min at 37° 
in growth medium by the addition of 37% (vol./vol.) formaldehyde to a final 
concentration of 1% (vol./vol.). The crosslinking reaction was stopped with 
glycine (from a 2.5 M stock) to a final concentration of 125 mM for 5 minutes 
at room temperature (quenches reaction). Nuclei were isolated from 5×10
5
 
cells, suspended in 1 ml of wash buffer (10 mmol/l Tris-HCl (pH 7.4), 15 
mmol/l NaCl, 60 mmol/l KCl and 1mmol/l CaCL2) and digested with 200 U of 
MNase (MNase) for 20 min at 37°. MNase digestion was stopped by adding 
100 mmol/l EDTA and 10 mmol/l EGTA  PH 7.5).  
RNA and proteins were degraded by adding of RNaseA (0,4 μg/μl), proteinase 
K (400 μg/ml) and NaCl (300mmol/l). Each sample was adjusted to 0.4% SDS 
and incubated overnight at 65° for deproteinization and crosslink reversal.  
MNase digested DNA were electrophoretically separated on 1.5% agarose gel 
and mononucleosome-size (150 bp) bands were excised from the gel and 
purified by PCR clean-up and gel extraction (Macherey-Nagel) according to 
the manufacturer’s instructions. The purified DNA was subsequently amplified 
by  quantitative real time RT-PCR using primers designed as follows: NUC 1, 
NUC 2, NUC 3 and CTRL R primer set for Pparγ promoter and NUC1, NUC2 
and CTRL R primer set for the Zfp423 promoter region. The primers used are 
listed in the table below (Table 3). 
 
NUC 1 Pparγ Forward 5′- TAATATCCCCTTAAGGAAGAAGCTC -3′ 
Reverse 5′- TGCTCAGGAACCATCGGGA -3 
NUC 2 Pparγ Forward 5'- CAAGGGCTGCTCCCACGTTA - 3' 
Reverse 5'- TGCTTAAGGCCTTTGCCCTTTT- 3' 
NUC 3 Pparγ Forward 5'-  TGTACAGTTCACGCCCCTCA - 3' 
Reverse 5'-  TTGTCTCGCCAGTGACCCAC - 3' 
CTRL R Pparγ Forward 5'- AGCCTTTATTCTGTCAACTATTCCT - 3' 
Reverse 5'- GGTCCAAAATGTTACTGCTATCCA - 3' 
NUC 1 Zfp423 Forward 5'- CCCGCACGGGCCTGTTA - 3' 
Reverse 5'-  CTCTGACAGCACTGGGCA - 3' 
NUC 2 Zfp423 Forward 5'-TGTGGCCGGACGCCTG - 3' 
Reverse 5'- CCTTCTCCTCCGCCCCTTG - 3' 
CTRL R Zfp423 Forward 5'- GCCCGAGGGCAGGCA - 3' 
Reverse 5'- GCACGGGCATTGCTCAG - 3' 
 
 Table 3. Primer sequences used in quantitative real time RT-PCR analysis. 
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3.5 Determination of DNA methylation status  
 
 Treatment of denatured single-stranded genomic DNA with sodium 
bisulfite is used to convert unmethylated cytosine residues to uracil residues, 
whereas methylated cytosine bases are protected from conversion and remain 
unchanged. In particular, bisulfite conversion consists of three sequential 
chemical steps: sulfonation of cytosine to cytosine-6-sulfonate, deamination to 
uracil-6-sulfonate, and desulfonation to uracil (Figure 13). 
 
 
 
Figure 13. The principle of the bisulfite conversion and chemical background. This 
procedure is based on the chemical modifications of cytosine residues in the presence of 
sodium bisulfite (HSO3−) at low pH and high temperatures. The chemistry of each reaction step 
is as follows: cytosine is sulfonated at the carbon-6 position and deaminated at the carbon-4 
position to generate uracil sulfonate.A subsequent desulfonation under alkaline completes the 
conversion, generating uracil from cytosine.  
 
 
Genomic DNA from cultured cells was extracted by DNA Purification Kit 
(Promega). Bisulfite treatment of extracting genomic DNA was performed by 
EZ DNA Methylation Kit (Zymo Research), following the manufacturer's 
instructions. The Pparγ and Zfp423 promoter region in the bisulfite converted 
genome was amplified by PCR using Bisulfite-specific primer sets. The 
Bisulfite Primer Seeker software (Zymo Research) was used to design the 
primers for CG-rich sequences on Pparγ and Zfp423 promoter region. The 
primers used are listed in the table below (Table 4). 
 
Pparγ Forward 5’-GATGTGTGATTAGGAGTTTTAATTAAA-3’ 
Reverse 5’-CAAACCTAAATTAACTAACACTATCCTAAC-3’ 
Zfp423 Forward 5’-GGTTTTATTATGTGTTTTTGTAGTGTA-3’ 
Reverse 5’-ATATCCCTCAACTCAACCTACTTAA- 3’ 
 
Table 4. Primer sequences used in quantitative real time RT-PCR analysis. 
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Converted DNA was amplified under the following conditions: 95° for                    
10 min and 39 cycles of 96° for 1 min, 58° for 1 min, and 72° for 2 min. For 
bisulfite sequencing, each PCR product of Pparγ and Zfp423 was subcloned 
using pGEM T-EASY Vector system (Promega). Then, competent E.coli cells 
were transformed and plated on X-GAL/IPTG LB-ampicillin Agar plates, 
where blue colonies represent an empty vector, and white colonies represent 
vectors inserted with target PCR product. Ten clones from each sample were 
selected and plasmids containing the target DNA are extracted by using the 
QIAprep Spin Miniprep Kit (QIAGEN) and subjected to standard sequencing 
analysis, using T7 universal primer and Big Dye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). All the procedures follow the 
manufacturer’s protocol. 
 
 
3.6 DNA sequencing by dideoxynucleotide chain termination method 
 DNA sequencing was carried out using the dideoxynucleotide chain 
termination method (Sanger et al. 1977) with dye terminator labeling of 
purified plasmids or PCR products. Specific forward and reverse primer for 
PCR products were used. The DNA samples were precipitated using ethanol 
and the pellets were washed twice with 70% ethanol.  
The ampliﬁed DNA was puriﬁed using the QIAquick PCR Purification kit 
(QIAGEN). The purified templates were dissolved in DEPC treated water and 
about 50 to 100 ng of PCR fragments (10 ng per 100 bp) were used in one 
reaction. The sequencing was performed on an ABI 3500 Automatic Sequencer 
(Applied Biosystems) using Big Dye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems).  
 
 
3.7 Luciferase reporter assay and methylation assay in vitro  
 
 The 5’-flanking region of Zfp423 gene (-1324 to -764) was amplified by 
PCR from genomic DNA prepared from NIH-3T3 cells, and the fragment was 
cloned into pCpGfree-Lucia (InvivoGen) luciferase reporter vector. 
Amplification of the reporter construct was carried out using Dam
-
/Dcm
-
 E.coli 
cells (New England Biolabs). The luciferase reporter vector was incubated with 
1 units/ug of M.SssI enzyme (methylates all CpG) and, with 1 units/ug of HhaI 
(modifies the cytosine residue of the sequence GCGC) and HpaII enzymes 
(methylates the cytosine residues in the sequence CCGG) in the presence of 
160 μM S-adenosylmethionine (SAM) at 37° for 1h. Methylation was 
confirmed by digestion of HpyCH4IV, a methylation-sensitive restriction 
enzyme. The full methylated, unmethylated and partially methylated Zfp423 
reporter vectors were transfected in NIH-3T3 cells, using lipofectamine.  
To normalize the luciferase activity, an amount of control plasmid encoding a 
Renilla luciferase gene was cotransfected into the cells.  
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After 48h, cells lysates were assayed for Firefly and Renilla luciferase activity 
using a single luciferase reporter assay kit, according to the manufacturer’s 
instructions. 
 
 
3.8 Statistical analysis  
 All data are presented as means ± SEM. The difference between groups 
was evaluated using the Student’s t-test. A p value less than 0.05 was 
considered significant. 
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4. RESULTS 
 
 
4.1 Zfp423 and Pparγ mRNA expression in 3T3-L1 and NIH-3T3 cells 
 
 Based on the aims above described, all the experiments were performed 
in two cellular models with a different adipogenic capability; the 3T3-L1 cells, 
which are fibroblasts committed to adipocyte lineage and are widely used to 
study in vitro adipogenesis; and the NIH-3T3 cells, which are fibroblasts with a 
low rate of adipogenic capability and are generally used in many studies as 
negative controls for in vitro adipogenesis.  
Firstly, the mRNA expression of both Zfp423 and Pparγ genes have been 
evaluated in both NIH-3T3 and 3T3-L1 cells by quantitative real time RT-
PCR. As shown in Figure 14, a 174.1-fold increase in Zfp423 mRNA and a 
394.7-fold up-regulation in Pparγ mRNA are detected in 3T3-L1 compared 
with NIH-3T3 cells. 
 
 
 
Figure 14. Zfp423 and Pparγ mRNA expression in NIH-3T3 and 3T3-L1 cells. Total RNA 
was isolated from cells and the mRNA levels of Zfp423 and Pparγ genes were assessed by 
quantitative real time RT-PCR in untreated 3T3-L1 and NIH-3T3 cells. Experimental 
normalization has been performed using the housekeeping Cyclophilin gene as internal control. 
Results are means ± SD from three independent experiments. **p<0.01, and ***p<0.001 vs 
NIH-3T3 in a 2-tailed Student’s t-test. 
 
 
Then, to exclude that the observed divergences in Zfp423 and Pparγ gene 
expression were associated with differences in the DNA sequence of these 
genes in the two cellular lines, Zfp423 and Pparγ promoters have been 
sequenced.  
The sequencing analysis of about 2000 bp of the promoter of each gene has 
revealed that the Zfp423 and Pparγ genes are genetically identical in 3T3-L1 
and NIH-3T3 cells (data not shown).  
These data, thus, indicate that the differences in the expression levels of Zfp23 
and Pparγ genes among NIH-3T3 and 3T3-L1 cells are not ascribable to the 
DNA sequences of their promoters, but are to be found. 
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4.2 DNA Methylation status of Zfp423 and Pparγ promoters in NIH-
3T3 and 3T3-L1  
  
 Then, to understand the reasons at the basis of the increased Zfp423 and 
Pparγ expression observed in 3T3-L1 cells, the contribution of DNA 
methylation in the transcriptional regulation of these two genes was examined 
and the specific methylation status of the two gene promoters was determined 
in vitro with appropriate experimental procedures in both NIH-3T3 and 3T3-L1 
cells.  
Firstly, by using the bioinformatic tool EMBOSS Cpgplot, I have identified 
CpG-rich sequences of Zfp423 and Pparγ promoters that may be sensitive to 
methylation. In details, in the Zfp423 promoter region a CpG-rich sequence 
containing 62 CpG sites located within 560 bp upstream the transcription start 
site (TSS) has been identified; whereas in the Pparγ promoter 4 CpGs, which 
methylation status has been already negatively correlated with Pparγ 
expression (Fujiki et al. 2009), have been found.  
Successively, I have established the methylation status of these CpG-rich 
sequences by sodium bisulfite sequencing in both NIH-3T3 and 3T3-L1 cells. 
The DNA methylation status of Zfp423 promoter is higher in NIH-3T3 
compared with 3T3-L1 cells [CpG methylation %: 90.2% (NIH-3T3) Vs 15.3% 
(3T3-L1)] (Figure 15A). The DNA methylation status of Pparγ promoter 
results to be more methylated in NIH-3T3 compared with 3T3-L1 cells, as well 
[CpG methylation %: 75.0% (NIH-3T3) Vs 30.0% (3T3-L1)] (Figure 15B). 
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Figure 15. DNA methylation of the Zfp423 and Pparγ promoters in NIH-3T3 and 3T3-L1 
cells. Bisulfite sequencing analysis of DNA methylation status and percentages of each 
methylated CpG sites in (A) Zfp423 and (B) Pparγ promoters in NIH-3T3 and 3T3-L1 cells. Each 
PCR product was sub-cloned and ten clones were analyzed by sodium bisulfite sequencing. 
The methylation profile of each CpG site in Zfp423 and Pparγ promoter, either methylated 
(black circles) or unmethylated (white circles), is aligned corresponding to their sequence order 
(as shown on the top of the figure for NIH-3T3 cells and 3T3-L1). 
 
 
Then, I have evaluated in vitro the causal relationship between the methylation 
status of the Zfp423 promoter and its mRNA expression.  
To this aim, I have cloned the Zfp423 promoter region into a luciferase reporter 
(pCpGfree-Lucia) vector, which was or completely methylated by M.SssI 
enzyme, or partially methylated by HhaI and HpaII enzymes, or not 
methylated.  
Methylation status of these vectors was confirmed by digestion with 
HpyCH4IV, a methylation-sensitive restriction enzyme (data not shown).  
I have, then, performed luciferase reporter assay in NIH-3T3 cells transiently 
transfected with the in vitro methylated, partially methylated, or unmethylated 
vectors. The luciferase activity of the fully methylated and of the partially 
methylated Zfp423 promoter region are reduced by about 80% and 40%, 
respectively, compared with the activity of the unmethylated region (Figure 
16). These results demonstrate that CpG methylation of Zfp423 promoter 
regulates Zfp423 gene transcription in vitro. 
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Figure 16.  DNA methylation effect of Zfp423 promoter activity. Luciferase activity of the in 
vitro methylated, partially methylated, or unmethylated Zfp423 promoter reporter constructs in 
NIH-3T3 cells. Relative luciferase activity normalized to the activity of a cotransfected internal 
vector is shown in the graph. Results are means ± SD from three independent experiments. 
***p<0.001 vs unmethylated vector, and #p<0.05 vs partially methylated vector in a 2-tailed 
Student’s t-test. 
 
 
4.3 Nucleosome occupancy of Zfp423 and Pparγ promoters in 3T3-
 L1 and NIH-3T3 cells 
 
 Next, I have wondered whether the differences in gene expression of 
Zfp423 and Pparγ in the two cellular systems may be linked to different 
nucleosome occupancy of the gene promoters.  
To predict nucleosome positioning on Zfp423 and Pparγ promoter regions, I 
have analysed the genomic sequence of these two genes using the 
bioinformatic tool NuPoP. As indicated in Figure 17, both the promoter regions 
of Zfp423 and Pparγ contain several potential regions for positioning of 
nucleosomes (Figure 17).  
Then, to validate the highest scores predicted nucleosomes and evaluate 
nucleosome occupancy on Zfp423 and Pparγ promoter regions among NIH-
3T3 and 3T3-L1 cells, I have firstly performed an MNase protection assay, 
which was followed by quantitative real time RT-PCR for the potential 
nucleosome sites. In detail, chromatin and genomic DNA purified from NIH-
3T3 and 3T3-L1 cells were digested with MNase (200 U) to obtain mono-
nucleosomal DNA fragments averaging 150 bp in size (Figure 17).  
Then, the potential positioning of nucleosome was checked in the mono-
nucleosomal DNA isolated from the agarose gel by quantitative real time RT-
PCR, using specific sets of primers for Pparγ promoter (NUC 1, NUC 2, NUC 
3 and CTRL R) and for Zfp423 promoter (NUC 1, NUC 2 and CTRL R). 
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Figure 17. A schematic representation of Pparγ and Zfp423 promoter regions. (A) Here are 
indicated the regions, relatively to the transcription start site, which are potentially occupied by 
nucleosomes on the Zfp423 promoter (NUC 1, NUC 2 and CTRL R) and on the Pparγ promoter 
(NUC 1, NUC 2, NUC 3 and CTRL R); (B) Genomic DNA obtained by nuclei lysis of 3T3-L1 and 
NIH-3T3 cells digested with 200 U of MNase for 20 min at 37°. Mono-nucleosomal DNA 
fragments averaging 150 bp in size have been obtained by MNase digestion. 
 
 
As shown in Figure 18, the percentage of nucleosome occupancy of three 
selected regions on the Pparγ promoter is higher in NIH-3T3 compared with 
3T3-L1 cells [NUC1 % of occupancy: 21.2% (3T3-L1) vs 62.0% (NIH-3T3); 
NUC2 % of occupancy: 9.2% (3T3-L1) vs 45.1% (NIH-3T3); NUC3 % of 
occupancy: 10.9% (3T3-L1) vs 53.1% (NIH-3T3)] (Figure 18).  
Similarly, the nucleosomes occupancy of Zfp423 promoter regions is also 
increased in NIH-3T3 compared with 3T3-L1 cells [NUC1 % of occupancy: 
51.5% (3T3-L1) vs 72.2% (NIH-3T3); NUC2 % of occupancy: 46.4% (3T3-
L1) vs 94.6% (NIH-3T3)] (Figure 18). 
As expected, no significant quantitative differences were found among the two 
cells in regions, which no nucleosomal positioning was predicted by the 
bioinformatic software.  
All these data indicate that the decreased nucleosome occupancy of the 3T3-L1  
inversely correlates with the increased expression levels of these two genes and 
thus suggest that both Pparγ and Zfp423 genes may be transcriptionally 
regulated by dynamic chromatin remodeling. 
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Figure 18. Nucleosome occupancy percentage of Zfp423 and Pparγ promoter regions in 
3T3-L1 and NIH-3T3 cells. The percentage of nucleosome occupancy was analysed by 
quantitative real time RT-PCR; A) in two regions of the Zfp423 promoter and B) in three regions 
of the Pparγ promoter. Results are means ± SD from three independent experiments. **p<0.01, 
and ***p<0.001 vs 3T3-L1 in a 2-tailed Student’s t-test. 
 
 
4.4 Contribution of DNA methylation to Zfp423 and Pparγ  expression 
  
 To evaluate how DNA methylation and/or nucleosome occupancy 
contribute to Zfp423 and Pparγ expression, I have tested the ability of the class 
II histone deacetylase inhibitor Trichostatin A (TSA) and of the DNA 
methyltransferase inhibitor AZA to remove the transcriptional block of Zfp423 
and Pparγ expression in NIH-3T3 cells. For this purpose, NIH-3T3 cells were 
exposed to TSA (330 nm) and to AZA  5 μM) for 24h and the Zfp423 and 
Pparγ gene expression was then determined by quantitative real time RT-PCR.  
As shown in Figure 19, the expression of Zfp423 and Pparγ mRNA is induced 
by AZA treatment compared with untreated cells. By contrast, treatment of 
cells with TSA does not affect both Zfp423 and Pparγ mRNA expression 
(Figure 19). 
NIH-3T3 cells were also treated for 6h with AZA, showing a greater increase 
in the expression of Zfp423 and Pparγ compared to expression levels observed 
after the 24h treatment (data not shown). 
Taken together these results demonstrate that DNA methylation rather than 
histone acetylation is the main epigenetic mechanism involved in the regulation 
of Zfp423 and Pparγ gene expression.   
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Figure 19. Zfp423 and Pparγ gene expression upon TSA and AZA treatment in NIH-3T3 
cells. Cells were cultured in growth medium containing 330 nM TSA or 5 µM AZA for 24h. 
Expression of Zfp423 and Pparγ mRNA were then measured by quantitative real time RT-PCR. 
Experimental normalization has been performed using the housekeeping Cyclophilin gene as 
internal control. Results are means ± SD from three independent experiments. **p<0.01, and 
***p<0.001 vs NIH-3T3 in a 2-tailed Student’s t-test. 
 
 
To further support the previous experiments, we performed an MNase 
protection assay in NIH-3T3 cells treated with AZA.  
As reported in Figure 20, the percentage of nucleosome occupancy of the 
previous investigated regions on the Pparγ promoter was lowered in AZA-
treated NIH-3T3 cells compared with NIH-3T3 cells [NUC1 % of occupancy: 
38.9% (NIH-3T3+AZA) vs 62.0% (NIH-3T3); NUC2% of occupancy: 37.4% 
(NIH-3T3+AZA) vs 45.1% (NIH-3T3); NUC3% of occupancy: 22.8% (NIH-
3T3+AZA) vs 53.1% (NIH-3T3)] (Figure 20).  
Similarly, the nucleosomes occupancy of Zfp423 promoter regions is also 
lowered in AZA-treated NIH-3T3 compared with NIH-3T3 cells [NUC1 % of 
occupancy: 65.1% (NIH-3T3+AZA) vs 72.2% (NIH-3T3); NUC2 % of 
occupancy: 46.9% (NIH-3T3+AZA) vs 94.6% (NIH-3T3)] (Figure 20).  
These results suggest that the inhibition of DNA methyltransferases restores 
the expression of these two genes by inducing chromatin remodeling on Zfp423 
and Pparγ promoters. 
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Figure 20. Nucleosome occupancy percentage of Zfp423 and Pparγ promoters in NIH-3T3 
cells treated with AZA. The percentage of nucleosome occupancy was analysed by 
quantitative real time RT-PCR in two regions of Zfp423 promoter and in three regions of the 
Pparγ promoter and. Results are means ± SD from three independent experiments. *p<0.05, 
and ***p<0.001 vs NIH-3T3  in a 2-tailed Student’s t-test. 
 
 
4.5 DNA methyltransferase inhibitor AZA treatment effect on 
 adipogenesis in NIH-3T3 cells  
  
 To examine the functional impact of these epigenetic changes, I have 
evaluated adipocyte differentiation in NIH-3T3 cells in the presence of AZA. 
In details, adipogenesis was induced using a differentiation cocktail, according 
to the Materials and Methods section, in presence or absence of the DNA 
methyltransferase inhibitor AZA.  
Adipocyte differentiation and the lipid content of NIH-3T3 cells were 
respectively assessed by evaluating the expression of the adipogenesis-related 
markers genes Pparγ, adipocyte lipid-binding protein (Ap2/Fabp4), 
adiponectin (AdipoQ), and Glut4 on days 0 and 7 of differentiation by 
quantitative real time RT-PCR, and by Oil Red O staining on day 7 of 
differentiation. In NIH-3T3, which, as previously said, are cells with a limited 
adipogenic capability, when adipogenic differentiation was induced there is 
only a slight increase in both the mRNA expression of the adipogenesis-related 
markers genes Pparγ, Ap2/Fabp4, AdipoQ and Glut4 and in the lipid 
accumulation upon Oil Red O staining (Figure 21). 
On the other hand, when AZA was administrated to cells in the post-confluent 
stage, AZA treatment robustly improves adipogenic differentiation as shown 
by the increased expression of Pparγ, Ap2/Fabp4, AdipoQ, and Glut4 
expression, as well as, by the increased lipid accumulation compared with the 
untreated control cells. 
These results suggest that the methylation of CpG sites in the promoter regions 
of Zfp423 and Pparγ genes promotes the adipocyte differentiation of non-
adipogenic NIH-3T3 cell line.   
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Figure 21. Effect of AZA on the differentiation of NIH-3T3 cells. Cells were cultured in the 
presence or absence of AZA during the period from days -2 to day 0 (post-confluent). Seven 
days upon adipocyte differentiation induction, gene expression, and lipid accumulation were 
assayed in cells treated or not with AZA. A) The relative mRNA levels of Pparγ, Ap2/Fabp4, 
AdipoQ and Glut4 were determined on days 0 and 7 of differentiation by quantitative real time 
RT-PCR. Experimental normalization has been performed using the housekeeping Cyclophilin 
gene as internal control. Results are means ± SD from three independent experiments. 
***p<0.001 vs NIH-3T3 Ctrl in a 2-tailed Student’s t-test. B) On days 0 and 7, cells were ﬁxed 
and stained with Oil red O. Representative images of Oil red O staining are shown. C) 
Quantification of adipocyte differentiation by Oil Red O staining. Quantities of Oil Red O are 
denoted as an Increased percentage of the untreated differentiated cells values. Results are 
means ± SD from three independent experiments. *p<0.05 vs NIH-3T3 in a 2-tailed Student’s t-
test. 
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5. DISCUSSION 
 
 
 Obesity, often defined as a condition of abnormal or excessive fat 
accumulation in the adipose tissue, is now the most common metabolic 
disorder in developed countries (Westley and May 2013; Caterson and Gill 
2002; Formiguera and Canton 2004; WHO 2004) and responsible, in the 
absence of immediate actions, of very serious health problems in the coming 
years. Indeed, obesity is associated with premature death and is universally 
recognized as major risk factor for metabolic disorders, such as insulin 
resistance, diabetes and cardiovascular disease (Fiel et al. 2001; Visscher and 
Seidell 2001).  
Accumulation of excess lipids in adipose tissue is due to the increase in 
adipocyte size (hypertrophy) and/or the recruitment of the new adipocytes from 
the resident pool of progenitor cells (hyperplasia) (Rosen and Spiegelman 
2014). Unlike to hyperplastic obesity, adipocyte hypertrophy is associated with 
impairment of glucose and lipid metabolism and loss of insulin sensitivity 
(Blüher 2013; Klöting and Blüher 2014). In addition, hypertrophic obesity is 
associated with adipose tissue dysfunction, inflammation, and local and 
systemic insulin resistance. Moreover, insulin sensitivity is inversely correlated 
with adipose cell size as well as restricted adipogenesis (Gustafson 2010; 
Gustafson et al. 2013).  
Hypertrophic obesity, indeed, is associated with an inability to recruit and 
differentiate new subcutaneous adipose cells. This is not due to lack of 
precursor cells but to the inability of these cells to be committed and/or to 
differentiate. Failures of inactivation of the canonical WNT signaling pathway, 
which inhibits adipocyte lineage commitment, and/or of Bmp4 signaling which 
instead promotes the commitment, are directly responsible for precursor cell 
restricted adipogenesis. However, the mechanisms involved are not fully 
understood yet.  
Thus, it is clear that understanding the underlying mechanisms responsible for 
the restricted adipogenesis characterizing hypertrophic obesity, may prevent 
the metabolic complications associated with obesity. 
In the last years, it has been identified Wisp2, as a novel adipokine, which has 
provided new insight into the crosstalk between WNT and Bmp4 signaling 
(Hammarstedt et al. 2013). Wisp2 expression is considerably higher in the 
subcutaneous adipose tissue than in visceral adipose tissue, and its expression 
is positively associated with hypertrophic obesity, markers of ectopic fat 
accumulation, and degree of insulin resistance (Hammarstedt et al. 2013). 
Wisp2 is highly expressed in early adipogenic precursor cells and prevents 
adipogenesis through, at least, two mechanisms: one of these is mediated by 
the secreted Wisp2, which inhibits adipogenesis with a still not completely 
known mechanism. The second one is mediated by retaining in the cytosol the 
transcriptional activator of Pparγ, Zfp423 (Hammarstedt et al. 2013). 
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Zfp423 is a zinc finger protein previously shown to regulate brain development 
(Warming et al. 2006; Cheng et al. 2007).  
It is highly expressed in preadipose rather than non-preadipose fibroblasts and 
very recently, it has been demonstrated that plays a critical role in 
adipogenesis. Ectopic expression of Zfp423 in non-adipogenic fibroblasts NIH-
3T3 activates Pparγ expression in undifferentiated cells, promoting adipocyte 
differentiation. In addition, in vivo analysis of Zfp423 in embryos obtained 
from Zfp423-deficient mouse showed impaired brown and white adipocyte 
differentiation, supporting the notion that Zfp423 is a critical regulator of 
preadipose cell determination of both brown and white fat depots (Gupta et al. 
2010). Furthermore, Gustafson recently demonstrated that Wisp2/Zfp423 
complex can be dissociated by Bmp4, thereby allowing Zfp423 to enter the 
nucleus, thus activating Pparγ expression, and committing these cells to the 
adipose lineage. In light of this, it is clear that identify the molecular 
mechanisms regulating Pparγ and Zfp423 gene expression could, at least 
partially, help to recognize the causes of the restricted adipogenesis observed in 
hypertrophic obesity. Indeed, what drives the restricted adipogenesis is 
currently unclear. This insufficiency could be ascribed to epigenetic 
modifications more than genetic polymorphism.  
In the present study, thus, I have investigated the contribution of epigenetic 
alterations in the development of restricted adipogenesis observed in 
hypertrophic obesity, focusing my attention on the role of Zfp423 and Pparγ 
gene itself.  
To this end, I have performed experiments in 3T3-L1 and NIH-3T3 cells. 
These cell lines have been extensively used in adipogenesis studies. Indeed, 
3T3-L1 cells are committed to adipocyte lineage whereas NIH-3T3 cells are 
non-adipogenic fibroblasts and negative control of adipogenesis (Fujiki et al. 
2009; Shao et al. 2013).  
In this study, comparing Zfp423 and Pparγ expression levels in 3T3-L1 and 
NIH-3T3 cells, I have demonstrated that the expression of both Zfp423 and 
Pparγ genes are higher in 3T3-L1 compared to NIH-3T3 cells. These data are 
in accordance with Gupta and colleagues, which have previously shown that 
the expression levels of Zfp423 are higher in several preadipose cell lines when 
compared to non-adipogenic fibroblasts. Additionally, they also demonstrate 
that in these preadipocyte cell lines, the expression of Zfp423 is not 
significantly modified during adipocyte differentiation (Gupta et al. 2010), 
indicating that is the basal expression of Zfp423 in the undifferentiated state 
that reflects the ability of these preadipose cell lines to differentiate.  
3T3-L1 and NIH-3T3 are a continuous substrain of 3T3-Swiss Albino cells 
developed through clonal isolation.  
Subsequently, I have demonstrated that the differences found in the expression 
levels of Zfp423 and Pparγ were not due to the presence of genetic mutations 
accumulated during the clonal isolation.  
Moreover, I have shown that methylation status of Zfp423 and Pparγ 
promoters is reduced in preadipose 3T3-L1 cells compared to non-adipogenic 
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fibroblasts NIH-3T3 and that the methylation level of each promoter inversely 
correlates with the expression level of its gene. These findings are in agreement 
with those previously reported by Fujiki and colleagues (Fujiki et al. 2009), 
who showed that the expression of Pparγ is repressed by DNA methylation in 
visceral adipose tissue of mouse models of diabetes.  
In addition to DNA methylation status, performing MNase digestion, a method 
which allows the determination of nucleosome occupancy and positioning, I 
have demonstrated that the reduced expression levels of Zfp423 and Pparγ 
genes are also regulated by chromatin remodeling. Indeed, genome regulation 
also occurs at the level of chromatin. Nucleosome packaging restricts protein 
binding and interferes with DNA-templated reactions. Local modulation of 
DNA accessibility thereby provides an opportunity to influence the 
fundamental processes of transcription, replication and repair. Some studies 
have uncovered cell-type-specific chromatin signature that suggests a dynamic 
interplay between tissue-specific regulation by transcription factors and 
chromatin structure and also can regulate adipocyte determination (Bell et al.  
2011). 
Subsequently, a MNase protection assay performed in NIH-3T3 cells treated 
with AZA clearly shown that the inhibition of DNMTs is able to restore the 
Zfp423 and Pparγ gene expression reducing not only the methylation levels but 
also the degree of chromatin compaction, promoting the recruitment and 
activation of the transcriptional machinery to the promoters of the investigated 
genes. These data clearly highlight that DNA methylation acts upstream of 
chromatin remodeling with a coordinated and synergistic action of DNMTs and 
histone modifying enzymes, confirming that DNA methylation may serve as a 
template for the establishment of certain histone modifications (Jin et al. 2011). 
Once I have determined that both Zfp423 and Pparγ are transcriptionally 
regulated by epigenetic modifications, I have investigated the effects of these 
epigenetic mechanisms on cell commitment. It is known that the exposure of 
proliferating stem cells derived from mouse embryos to DNA methylation 
inhibitor results in a subpopulation of cells with the ability to undergo 
commitment to new cell phenotypes (Taylor and Jones 1979). In light of this, 
adipocyte differentiation was induced in NIH-3T3 cells treated with AZA for 
6h before the administration of differentiation cocktail. AZA treatment has 
revealed a significant improvement in adipogenic differentiation, suggesting 
that AZA treatment may induce Zfp423 and Pparγ gene expression, promoting 
adipocyte commitment and differentiation of NIH-3T3 cells. 
In accordance with my data, several studies support the hypothesis that the 
block of DNA methylation induces the stable expression of one or few genes 
responsible for lineage commitment (Pinney and Emerson 1989; Taylor and 
Jones 1979). Indeed, Lane and colleagues have previously shown that the 
exposure of proliferating 10T1/2 stem cells (derived from mouse embryos) to 
AZA gave rise to a subpopulation of cells with the capacity to differentiate into 
adipocytes upon treatment with terminal differentiation inducers, and have also 
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provided convincing evidence for the participation of Bmp4 in adipocyte 
lineage determination (Bowers et al. 2006).  
Although this study highlights the importance of Bmp4, no alterations in Bmp4 
methylation are identified. Although this study highlights the importance of 
Bmp4, my data provide supporting evidence that methylation of Zfp423 and 
Pparγ controls preadipocyte determination in NIH-3T3 cells.   
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6. CONCLUSIONS 
 
 
 In this study, I have demonstrated that: i) Zfp423 and Pparγ, main genes 
involved in the commitment and differentiation are differentially expressed in 
3T3-L1 and NIH-3T3 cells; ii) the expression differences are not due to the 
presence of genetic mutations in the promoter sequence of Zfp423 and Pparγ 
genes; iii) Zfp423 and Pparγ genes are transcriptionally regulated by DNA 
methylation and chromatin remodelling, iiii) the inhibition of DNA-
methyltransferase restores the expression of Zfp423 and Pparγ, induces 
chromatin remodeling of their promoters, and improve the adipocyte 
commitment and differentiation of the NIH-3T3 cell line. Taken together, these 
results suggest that epigenetic mechanisms could impact on the expression of 
these two key modulators of adipocyte differentiation, resulting in the 
modulation of the adipogenic process. 
My observations are the starting point for a better understanding of these 
pathophysiological alterations. Indeed, a complete understanding of molecular 
mechanisms regulating the expression of Zfp423 and Pparγ genes may provide 
novel therapeutic strategies for the treatment of obesity-related comorbidities. 
Meanwhile, identify the environmental factors that lead to epigenetics changes 
in these two genes, could play a critical role in the prevention of hypertrophic 
obesity and its related metabolic complications. 
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